BRPI1009003A2 - "método para expressão recombinante de um ccn1 humano, uso de um ccn1 humano, anticorpo contra ccn1 humano, uso de um anticorpo contra ccn1 humano, método para a fabricação de um medicamento para o tratamento de doenças e composição farmacêutica" - Google Patents

"método para expressão recombinante de um ccn1 humano, uso de um ccn1 humano, anticorpo contra ccn1 humano, uso de um anticorpo contra ccn1 humano, método para a fabricação de um medicamento para o tratamento de doenças e composição farmacêutica"

Info

Publication number: BRPI1009003A2
Authority: BR; Brazil
Prior art keywords: human ccn1; ccn1; antibody against; against human; medicament
Prior art date: 2009-06-04

Application number

BRPI1009003A

Other languages

English (en)

Inventor

Dirk Ponsel

Engin Toksoez

Hans-Willi Krell

Hendrik Knoetgen

Jens Niewoehner

Sandra Miller

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-06-04

Filing date

2010-06-02

Publication date

2016-03-08

2010-06-02 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2016-03-08 Publication of BRPI1009003A2 publication Critical patent/BRPI1009003A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Toxicology (AREA)
Wood Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Plant Pathology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

BRPI1009003A 2009-06-04 2010-06-02 "método para expressão recombinante de um ccn1 humano, uso de um ccn1 humano, anticorpo contra ccn1 humano, uso de um anticorpo contra ccn1 humano, método para a fabricação de um medicamento para o tratamento de doenças e composição farmacêutica" BRPI1009003A2 (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP09007389		2009-06-04
EP09164765		2009-07-07
EP09165886		2009-07-20
PCT/EP2010/003355 WO2010139469A2 (en)	2009-06-04	2010-06-02	Antibodies against human ccn1 and uses thereof

Publications (1)

Publication Number	Publication Date
BRPI1009003A2 true BRPI1009003A2 (pt)	2016-03-08

Family

ID=42735668

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1009003A BRPI1009003A2 (pt)	2009-06-04	2010-06-02	"método para expressão recombinante de um ccn1 humano, uso de um ccn1 humano, anticorpo contra ccn1 humano, uso de um anticorpo contra ccn1 humano, método para a fabricação de um medicamento para o tratamento de doenças e composição farmacêutica"

Country Status (14)

Country	Link
US (2)	US8207307B2 (pt)
EP (1)	EP2438084A2 (pt)
JP (1)	JP2012528812A (pt)
KR (1)	KR20120014941A (pt)
CN (1)	CN102414219A (pt)
AR (1)	AR076948A1 (pt)
AU (1)	AU2010256000A1 (pt)
BR (1)	BRPI1009003A2 (pt)
CA (1)	CA2762375A1 (pt)
IL (1)	IL216440A0 (pt)
MX (1)	MX2011012555A (pt)
SG (1)	SG176666A1 (pt)
TW (1)	TW201102086A (pt)
WO (1)	WO2010139469A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN106492188B (zh) *	2014-02-08	2019-12-20	德赛诊断系统(上海)有限公司	Cyr61/CCN1蛋白抗原表位多肽及其抑制剂和单抗及其应用
EP3364190A1 (en) *	2017-02-20	2018-08-22	Panka Cancer Research AG	Method of detecting cancer or cancer cells
KR102721254B1 (ko) *	2017-02-28	2024-10-23	주식회사 파이안바이오테크놀로지	형질전환시킨 중국햄스터난소 세포를 활용하여 시시엔5 단백질을 제조하는 방법
EP3711772A1 (en) *	2019-03-20	2020-09-23	Oslo Universitetssykehus HF	Recombinant proteins and fusion proteins
CN116715761B (zh) *	2023-07-31	2024-01-26	中国科学院苏州纳米技术与纳米仿生研究所	一种治疗性单克隆抗体及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en)	1985-06-19	1990-11-14	Ajinomoto Co., Inc.	Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
EP0804562B1 (en)	1994-07-12	2002-10-09	Human Genome Sciences, Inc.	Connective tissue growth factor-2
US7521540B2 (en)	1996-03-15	2009-04-21	Munin Corporation	CYR61 compositions and methods
CA2248549A1 (en) *	1996-03-15	1997-09-18	Munin Corporation	Extracellular matrix signalling molecules
ATE360643T1 (de)	2000-01-31	2007-05-15	Munin Corp	Humanes cyr61
WO2001098359A2 (en)	2000-06-21	2001-12-27	Wyeth	Cyr61 as a target for treatment and diagnosis of breast cancer
EP1373299A4 (en)	2000-07-11	2005-01-19	Human Genome Sciences Inc	Connective tissue GROWTH FACTOR-2
AU2001296477A1 (en)	2000-09-29	2002-04-08	Wyeth	Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
WO2005040191A2 (en)	2003-06-20	2005-05-06	Munin Corporation	Ccn1 compositions and methods
JP2009511067A (ja) *	2005-10-14	2009-03-19	メディミューン，エルエルシー	抗体ライブラリーの細胞提示

2010
- 2010-06-01 TW TW099117631A patent/TW201102086A/zh unknown
- 2010-06-02 JP JP2012513508A patent/JP2012528812A/ja active Pending
- 2010-06-02 AU AU2010256000A patent/AU2010256000A1/en not_active Abandoned
- 2010-06-02 KR KR1020127000109A patent/KR20120014941A/ko not_active Ceased
- 2010-06-02 MX MX2011012555A patent/MX2011012555A/es not_active Application Discontinuation
- 2010-06-02 SG SG2011089687A patent/SG176666A1/en unknown
- 2010-06-02 AR ARP100101940A patent/AR076948A1/es not_active Application Discontinuation
- 2010-06-02 BR BRPI1009003A patent/BRPI1009003A2/pt not_active Application Discontinuation
- 2010-06-02 WO PCT/EP2010/003355 patent/WO2010139469A2/en not_active Ceased
- 2010-06-02 CA CA2762375A patent/CA2762375A1/en not_active Abandoned
- 2010-06-02 EP EP10736604A patent/EP2438084A2/en not_active Withdrawn
- 2010-06-02 CN CN2010800194420A patent/CN102414219A/zh active Pending
- 2010-06-03 US US12/793,147 patent/US8207307B2/en not_active Expired - Fee Related
2011
- 2011-11-17 IL IL216440A patent/IL216440A0/en unknown
2012
- 2012-04-13 US US13/445,983 patent/US20120258112A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US8207307B2 (en)	2012-06-26
WO2010139469A3 (en)	2011-03-31
MX2011012555A (es)	2011-12-14
AR076948A1 (es)	2011-07-20
CN102414219A (zh)	2012-04-11
JP2012528812A (ja)	2012-11-15
WO2010139469A2 (en)	2010-12-09
IL216440A0 (en)	2012-02-29
US20120258112A1 (en)	2012-10-11
SG176666A1 (en)	2012-01-30
CA2762375A1 (en)	2010-12-09
US20100310567A1 (en)	2010-12-09
EP2438084A2 (en)	2012-04-11
WO2010139469A8 (en)	2011-11-17
KR20120014941A (ko)	2012-02-20
TW201102086A (en)	2011-01-16
AU2010256000A1 (en)	2011-11-17

Similar Documents

Publication	Publication Date	Title
BR112012022211A2 (pt)	2017-07-18	composto. composição farmacêutica, método de tratamento de uma doença meidada por h4r, método de inibição de h4h, método de tratamento da dor ou inflamação resultante de cirurgia de catarata, método para atingir um efeito em um paciente e uso de uma composto
BRPI0923589A2 (pt)	2016-07-26	uso de uma composição espumável essencialmente livre de ingredientes farmaceuticamente ativos para o tratamento da pele humana.
UA94734C2 (ru)	2011-06-10	ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
BR112012017536A2 (pt)	2018-06-05	"material compósito adequado para implante para o corpo humano, implante protético, método para fabricar implante,método de tratamento terapêutico, estético e ou cosmético e uso de um tratamento de superficie em uma superficie de um microlumen em um gel polimérico
BRPI0820568A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
EA201270221A1 (ru)	2012-08-30	Лечение болезни крона с применением лаквинимода
BRPI0924460A2 (pt)	2018-03-27	composição farmacêutica para uso em oftalmologia médica e veterinária
BRPI0812738A2 (pt)	2014-09-30	Composto, sal farmceuticamente aceitável, composição farmacêutica, uso de um composto, e, método par ao tratamento de uma infecção viral em um humano
BRPI1013394A2 (pt)	2016-06-21	"composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c."
BRPI0615157A2 (pt)	2016-09-13	composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto
BRPI1008145A2 (pt)	2016-03-15	proteína de ligação de antígeno biespecífico, método para preparação de uma proteína de ligação de antígeno biespecífico, célula hospedeira, composição farmacêutica, uso da proteína de ligação de antígeno biespecífico e método para o tratamento de um paciente.
BRPI1012993A2 (pt)	2018-01-16	"uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro"
BRPI0807285A2 (pt)	2014-05-06	"composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
IL215579A (en)	2015-06-30	Use of 1-benzyl-3-hydroxymethylindazole history to prepare medicinal products for the treatment of diseases based on the expression of 1-mcp, cx3cr1 and 40p
BRPI1009392A2 (pt)	2016-03-08	"formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
FI20135146A7 (fi)	2013-02-15	Farmaseuttiset koostumukset ja hoitomenetelmät
WO2010010551A3 (en)	2010-05-14	Angiopoietin derived peptides
BRPI0911203A2 (pt)	2016-07-05	peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
CL2007003472A1 (es)	2008-08-22	Sal fumarato de (alfa s,beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamie
PH12013500108A1 (en)	2017-01-06	Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
BR112012003280A2 (pt)	2017-05-23	composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
IL197575A (en)	2013-06-27	A method for removing adult stem cells from the blood, using them to prepare drugs for the treatment of lesions, and a medical preparation containing these adult GES cells
BRPI0914371A2 (pt)	2019-09-24	"composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação"
BRPI0919231A2 (pt)	2018-01-09	agonista de receptor de neuropeptídeo-2, composição farmacêutica que o compreende, seu uso e método para o tratamento ou profilaxia de enfermidades
BR112014010139A2 (pt)	2017-04-25	formulação farmacêutica, método de redução do nível de açúcar no sangue de um paciente e polipeptídeo

Legal Events

Date	Code	Title	Description
2016-05-24	B11A	Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
2016-08-16	B11Y	Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]